Business Context and Reporting Period
This Form 8-K filing by E. I. du Pont de Nemours and Company (DuPont) is dated March 31, 2017. The report details a material definitive agreement entered into with FMC Corporation and an amendment to the existing merger agreement with The Dow Chemical Company. These actions are driven by regulatory commitments made to the European Commission regarding the proposed merger of equals between DuPont and Dow.
Key Financial Metrics and Transaction Values
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins for the reporting period. However, it discloses specific financial terms related to the transaction with FMC:
- Cash Payment: FMC will pay DuPont $1.2 billion in cash, subject to adjustments, reflecting the net value difference between the businesses being exchanged.
- Net Working Capital: DuPont will retain accounts receivable and payable associated with the divested assets, with an expected net value of $425 million.
- Revenue Threshold: The agreement defines a "Substantial Detriment" as a one-year loss of revenues in excess of $350 million (based on fiscal year 2016 annual revenues) that would result from specific regulatory actions.
Material Changes and Transaction Details
The filing outlines a significant restructuring of DuPont's portfolio to satisfy antitrust conditions:
- Divestiture to FMC: DuPont agreed to sell its Crop Protection business assets and R&D organization (excluding seed treatment, nematicides, and late-stage R&D). Specific portfolios include Cereal Broadleaf Herbicides and Chewing Insecticides.
- Acquisition from FMC: DuPont agreed to purchase FMC's Health and Nutrition business segment, excluding Omega-3 products.
- Merger Agreement Amendment: DuPont and Dow amended their Merger Agreement to extend the "Outside Date" (the deadline to close the merger) from June 15, 2017, to August 31, 2017. The amendment also restricts DuPont from agreeing to divestitures that would cause a "Substantial Detriment."
Guidance, Outlook, and Risks
Outlook and Timing:
- DuPont expects to close the transactions with FMC in the fourth quarter of 2017.
- DuPont and Dow expect to close their merger in August 2017.
- Closing is contingent on the Dow merger closing prior to or concurrently with the FMC transactions.
- Approval is required from governmental entities, including the European Commission and the U.S. Department of Justice.
- Receipt of domestic and foreign competition law approvals is required.
- Regulatory Risk: Failure to obtain necessary approvals could prevent the transactions from closing.
- Integration Risk: Uncertainty regarding the successful integration of the acquired Health and Nutrition business and the realization of anticipated synergies.
- Operational Disruption: Potential harm to current business operations and plans during the pendency of the transactions.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially due to risks such as litigation, capital availability, and economic developments.
Key Facts for Investor Verification
- Verify the status of regulatory approvals from the European Commission and U.S. Department of Justice for the FMC transaction.
- Monitor the progress of the DowDuPont merger, as the FMC transaction is contingent upon its closing.
- Confirm the final closing dates for both the FMC asset exchange and the Dow merger, noting the new August 31, 2017, deadline for the latter.
- Assess the potential impact of the divestiture of Crop Protection assets on DuPont's future revenue streams and R&D capabilities.
- Review the definition of "Substantial Detriment" to understand the limits on further divestitures during the merger process.